RxDoctor Payments Data

Tina Walker

Family · Eustis, FLNPI 1588308860

Payments from drug & device makers

$581in general payments, 2019–2025

Across 23 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$125
  • Lilly USA, LLC$124
  • Exact Sciences$82
  • Novo Nordisk$42
  • Pfizer$41
  • Smith+Nephew$30
  • plus $137 from 7 others

What the payments were for

  • Food & beverage$581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$581 in reported general payments places this provider in the 55th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$117,335
Medicare patients
557
Services billed
2,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$87,689
JardianceEmpagliflozin23$26,940
XareltoRivaroxaban21$23,128
JanuviaSitagliptin Phosphate23$18,881
MounjaroTirzepatide13$17,494
OzempicSemaglutide15$16,607
TrulicityDulaglutide14$16,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,593
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,500
Metoprolol Succinate190$3,505
Atorvastatin Calcium313$3,330
Levothyroxine Sodium275$2,853
SynthroidLevothyroxine Sodium27$2,588
Omeprazole159$2,368
Rosuvastatin Calcium177$2,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$87,68987 claims
Lilly USA, LLCMounjaro, Trulicity$124$34,08727 claims
Novo NordiskOzempic$42$16,60715 claims
GSKTrelegy Ellipta$17$12,59312 claims
AstraZenecaBreztri Aerosphere$20$8,50012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 14,618 family providers in Florida.

Other family in Eustis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →